Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LOXO-260 · 1 trial · 2 indications
DLT rate
| Arm | Type | Description |
|---|---|---|
| Phase 1A: LOXO-260 Dose Escalation | EXPERIMENTAL | LOXO-260 administered orally |
| Phase 1B: LOXO-260 Dose Expansion | EXPERIMENTAL | LOXO-260 administered orally |
| Name | Type | Description |
|---|---|---|
| LOXO-260 | DRUG | Oral |
Inclusion Criteria: * Must be ≥ 18 years of age at the time of signing the informed consent (Phase 1a and Phase 1b). Patients 12 years and older may be enrolled in Phase 1b for countries and sites where approved. * Must have evidence of a previously documented RET fusion (solid tumors) or RET mutat...
LOXO-260 is an investigational small molecule being studied for the treatment of non-small-cell lung carcinoma and thyroid neoplasms. It is intended for cancer patients who have a change in the RET gene that has not responded to prior treatment. The drug is currently in Phase 1 clinical development.
LOXO-260 targets cancers driven by alterations in the RET gene. It is designed for patients whose tumors have a RET gene change that has not responded to previous therapy. The drug is being evaluated in a Phase 1 clinical trial for its safety and efficacy in this patient population.
LOXO-260 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The drug is currently in Phase 1 clinical development for the treatment of RET-altered cancers, including non-small-cell lung carcinoma and thyroid neoplasms.
LOXO-260 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial, which has been completed, enrolled 70 participants and was conducted in the United States and France.
LOXO-260 has one completed Phase 1 clinical trial, identified as NCT05241834. The study, titled 'A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment,' enrolled 70 participants with non-small-cell lung carcinoma and thyroid neoplasms. The trial was conducted in the United States and France.
LOXO-260 is the primary name used for this investigational drug. No alternative names have been reported for this compound in the available clinical trial information. It is being developed by Eli Lilly and Company for the treatment of RET-altered cancers.